LUBBOCK, Texas (press release) – The following is a press release from Texas Tech University:
On August 18, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded grants to two researchers from the Texas Tech University Health Sciences Center (TTUHSC).
C. Patrick Reynolds, MD, Ph.D., director of the TTUHSC School of Medicine Cancer Center, was named the recipient of the Texas Regional Excellence in Cancer Award. He will receive a planned amount of $ 5,999,936 to fund a new Center of Excellence in Developmental Cancer Therapy at TTUHSC.
In addition, William “Trey” Putnam, Ph.D., Professor of Pharmacy Practice and Pharmaceutical Sciences at TTUHSC Jerry H. Hodge School of Pharmacy, received a Core Facility Support Award, which will provide an expected amount of 2,965,226 $ to support the purchase of a new basic instrumentation and support infrastructure for the North Texas Clinical Pharmacology Cancer Core (NTCPCC).
“Our new CPRIT grant supports several faculty projects here in Lubbock and at the Amarillo and Abilene School of Pharmacy,” said Reynolds. “It is also supporting the recruitment of new faculty at TTUHSC and some core cancer research resources. “
Reynolds said the grant would provide support to different faculty researchers each year. In the first year, the grant will focus on projects related to brain tumors and breast, colon and pancreatic cancers.
Junior faculty members and their mentors who will receive first year support include Yangzom Bhutia, DVM, Ph.D., Lubbock (Mentor: Vadivel Ganapathy, Ph.D., Lubbock); Nadezhda German, Ph.D., Amarillo (Mentor: Thomas Abbruscato, Ph.D., Amarillo); Chinnadurai Mani, Ph.D., Lubbock (mentor: Komaraiah Palle, Ph.D., Lubbock); and Devin B. Lowe, Ph.D., Abilene (mentor: Sanjay Srivastava, Ph.D., Abilene).
Reynolds, professor emeritus at the university, also heads the South Plains Cancer Consortium and the Childhood Oncology Group Childhood Cancer Repository, powered by Alex’s Lemonade Stand Foundation. The repository, based at TTUHSC, collects, preserves and distributes validated childhood cancer cell lines to researchers around the world studying childhood cancer.
Putnam said the continued support provided by CPRIT will allow the NTCPCC to be better positioned to facilitate translational oncology research by purchasing updated and state-of-the-art mass spectrometers and supporting a team of scientists to expand the information obtained during the development of cancer drugs. therapeutic. The new mass spectrometers will help the NTCPCC achieve its goal of maximizing the amount of information obtained from each valuable clinical sample.
“The additional funding will allow the purchase of a Sciex 7500 QTRAP, one of the most sensitive quantitative mass spectrometers on the market,” said Putnam. “This increased sensitivity will allow better determination of PK, PD and metabolism in experimental cancer therapies. “
The grant will also allow the NTCPCC to purchase a Sciex ZenoTOF 7600 system, one of the most sensitive high-resolution Q-TOF systems commercially available, which will allow the NTCPCC to probe clinical samples more deeply.
“The ZenoTOF 7600 system mass spectrometer will dramatically improve the capabilities of the NTCPCC,” Putnam said. “Being one of the first laboratories to have this instrumentation means that the NTCPCC will be able to conduct unique experiments that bring value to the clinical cancer community. In addition, this instrument allows clinical samples to be profiled and essentially all mass spectral information to be collected for later interrogation, as needed. “
(Texas Tech University press release)